Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 464

1.

Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations.

Sakornsakolpat P, Prokopenko D, Lamontagne M, Reeve NF, Guyatt AL, Jackson VE, Shrine N, Qiao D, Bartz TM, Kim DK, Lee MK, Latourelle JC, Li X, Morrow JD, Obeidat M, Wyss AB, Bakke P, Barr RG, Beaty TH, Belinsky SA, Brusselle GG, Crapo JD, de Jong K, DeMeo DL, Fingerlin TE, Gharib SA, Gulsvik A, Hall IP, Hokanson JE, Kim WJ, Lomas DA, London SJ, Meyers DA, O'Connor GT, Rennard SI, Schwartz DA, Sliwinski P, Sparrow D, Strachan DP, Tal-Singer R, Tesfaigzi Y, Vestbo J, Vonk JM, Yim JJ, Zhou X, Bossé Y, Manichaikul A, Lahousse L, Silverman EK, Boezen HM, Wain LV, Tobin MD, Hobbs BD, Cho MH; SpiroMeta Consortium; International COPD Genetics Consortium.

Nat Genet. 2019 Mar;51(3):494-505. doi: 10.1038/s41588-018-0342-2. Epub 2019 Feb 25.

PMID:
30804561
2.

Divergent effects of repeated cocaine and novel environment exposure on locus coeruleus c-fos expression and brain catecholamine concentrations in rats.

Lisieski MJ, Karavidha K, Gheidi A, Garibyan RL, Conti AC, Morrow JD, Perrine SA.

Brain Behav. 2019 Feb 20:e01222. doi: 10.1002/brb3.1222. [Epub ahead of print]

3.

Do sputum or circulating blood samples reflect the pulmonary transcriptomic differences of COPD patients? A multi-tissue transcriptomic network META-analysis.

Faner R, Morrow JD, Casas-Recasens S, Cloonan SM, Noell G, López-Giraldo A, Tal-Singer R, Miller BE, Silverman EK, Agustí A, Hersh CP.

Respir Res. 2019 Jan 8;20(1):5. doi: 10.1186/s12931-018-0965-y.

4.

Single prolonged stress decreases sign-tracking and cue-induced reinstatement of cocaine-seeking.

Fitzpatrick CJ, Jagannathan L, Lowenstein ED, Robinson TE, Becker JB, Morrow JD.

Behav Brain Res. 2019 Feb 1;359:799-806. doi: 10.1016/j.bbr.2018.07.026. Epub 2018 Aug 2.

PMID:
30077578
5.

Integrative genomics identifies new genes associated with severe COPD and emphysema.

Sakornsakolpat P, Morrow JD, Castaldi PJ, Hersh CP, Bossé Y, Silverman EK, Manichaikul A, Cho MH.

Respir Res. 2018 Mar 22;19(1):46. doi: 10.1186/s12931-018-0744-9.

6.

Ensemble genomic analysis in human lung tissue identifies novel genes for chronic obstructive pulmonary disease.

Morrow JD, Cho MH, Platig J, Zhou X, DeMeo DL, Qiu W, Celli B, Marchetti N, Criner GJ, Bueno R, Washko GR, Glass K, Quackenbush J, Silverman EK, Hersh CP.

Hum Genomics. 2018 Jan 15;12(1):1. doi: 10.1186/s40246-018-0132-z.

7.

Human Lung DNA Methylation Quantitative Trait Loci Colocalize with Chronic Obstructive Pulmonary Disease Genome-Wide Association Loci.

Morrow JD, Glass K, Cho MH, Hersh CP, Pinto-Plata V, Celli B, Marchetti N, Criner G, Bueno R, Washko G, Choi AMK, Quackenbush J, Silverman EK, DeMeo DL.

Am J Respir Crit Care Med. 2018 May 15;197(10):1275-1284. doi: 10.1164/rccm.201707-1434OC.

PMID:
29313708
8.

Meta-analysis of peripheral blood gene expression modules for COPD phenotypes.

Reinhold D, Morrow JD, Jacobson S, Hu J, Ringel B, Seibold MA, Hersh CP, Kechris KJ, Bowler RP.

PLoS One. 2017 Oct 9;12(10):e0185682. doi: 10.1371/journal.pone.0185682. eCollection 2017.

9.

Name that tune: Mitigation of driver fatigue via a song naming game.

Trumbo MC, Jones AP, Robinson CSH, Cole K, Morrow JD.

Accid Anal Prev. 2017 Nov;108:275-284. doi: 10.1016/j.aap.2017.09.002. Epub 2017 Sep 18.

PMID:
28926804
10.

Subtyping Chronic Obstructive Pulmonary Disease Using Peripheral Blood Proteomics.

Zarei S, Mirtar A, Morrow JD, Castaldi PJ, Belloni P, Hersh CP.

Chronic Obstr Pulm Dis. 2017 Feb 8;4(2):97-108. doi: 10.15326/jcopdf.4.2.2016.0147.

11.

Isopropyl Alcohol Swabs as a Preferred Substance of Abuse.

Sharma A, Morrow JD.

J Psychoactive Drugs. 2017 Jul-Aug;49(3):258-261. doi: 10.1080/02791072.2017.1290302. Epub 2017 Feb 26.

PMID:
28632074
12.

Thalamic mast cell activity is associated with sign-tracking behavior in rats.

Fitzpatrick CJ, Morrow JD.

Brain Behav Immun. 2017 Oct;65:222-229. doi: 10.1016/j.bbi.2017.05.003. Epub 2017 May 6.

13.

Functional interactors of three genome-wide association study genes are differentially expressed in severe chronic obstructive pulmonary disease lung tissue.

Morrow JD, Zhou X, Lao T, Jiang Z, DeMeo DL, Cho MH, Qiu W, Cloonan S, Pinto-Plata V, Celli B, Marchetti N, Criner GJ, Bueno R, Washko GR, Glass K, Quackenbush J, Choi AM, Silverman EK, Hersh CP.

Sci Rep. 2017 Mar 13;7:44232. doi: 10.1038/srep44232.

14.

Sex-Based Genetic Association Study Identifies CELSR1 as a Possible Chronic Obstructive Pulmonary Disease Risk Locus among Women.

Hardin M, Cho MH, Sharma S, Glass K, Castaldi PJ, McDonald ML, Aschard H, Senter-Sylvia J, Tantisira K, Weiss ST, Hersh CP, Morrow JD, Lomas D, Agusti A, Bakke P, Gulsvik A, O'Connor GT, Dupuis J, Hokanson J, Crapo JD, Beaty TH, Laird N, Silverman EK, DeMeo DL; COPDGene and Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-Points Investigators.

Am J Respir Cell Mol Biol. 2017 Mar;56(3):332-341. doi: 10.1165/rcmb.2016-0172OC.

15.

Lesions of the ventral hippocampus attenuate the acquisition but not expression of sign-tracking behavior in rats.

Fitzpatrick CJ, Creeden JF, Perrine SA, Morrow JD.

Hippocampus. 2016 Nov;26(11):1424-1434. doi: 10.1002/hipo.22619. Epub 2016 Jul 30.

16.

Subanesthetic ketamine decreases the incentive-motivational value of reward-related cues.

Fitzpatrick CJ, Morrow JD.

J Psychopharmacol. 2017 Jan;31(1):67-74. doi: 10.1177/0269881116667709. Epub 2016 Sep 26.

17.

DNA methylation profiling in human lung tissue identifies genes associated with COPD.

Morrow JD, Cho MH, Hersh CP, Pinto-Plata V, Celli B, Marchetti N, Criner G, Bueno R, Washko G, Glass K, Choi AM, Quackenbush J, Silverman EK, DeMeo DL.

Epigenetics. 2016 Aug 26:1-10. [Epub ahead of print]

18.

Neurobiology of Adolescent Substance Use Disorders.

Sharma A, Morrow JD.

Child Adolesc Psychiatr Clin N Am. 2016 Jul;25(3):367-75. doi: 10.1016/j.chc.2016.02.001. Epub 2016 Apr 9. Review.

PMID:
27338961
19.

Pavlovian Conditioned Approach Training in Rats.

Fitzpatrick CJ, Morrow JD.

J Vis Exp. 2016 Feb 4;(108):e53580. doi: 10.3791/53580.

20.

Neuroscience of resilience and vulnerability for addiction medicine: From genes to behavior.

Morrow JD, Flagel SB.

Prog Brain Res. 2016;223:3-18. doi: 10.1016/bs.pbr.2015.09.004. Epub 2015 Nov 23. Review.

PMID:
26806768
21.

Sign-trackers have elevated myo-inositol in the nucleus accumbens and ventral hippocampus following Pavlovian conditioned approach.

Fitzpatrick CJ, Perrine SA, Ghoddoussi F, Galloway MP, Morrow JD.

J Neurochem. 2016 Mar;136(6):1196-1203. doi: 10.1111/jnc.13524. Epub 2016 Jan 19.

22.

Rats that sign-track are resistant to Pavlovian but not instrumental extinction.

Ahrens AM, Singer BF, Fitzpatrick CJ, Morrow JD, Robinson TE.

Behav Brain Res. 2016 Jan 1;296:418-430. doi: 10.1016/j.bbr.2015.07.055. Epub 2015 Jul 30.

23.

Identifying a gene expression signature of frequent COPD exacerbations in peripheral blood using network methods.

Morrow JD, Qiu W, Chhabra D, Rennard SI, Belloni P, Belousov A, Pillai SG, Hersh CP.

BMC Med Genomics. 2015 Jan 13;8:1. doi: 10.1186/s12920-014-0072-y.

24.

Sign-tracking to an appetitive cue predicts incubation of conditioned fear in rats.

Morrow JD, Saunders BT, Maren S, Robinson TE.

Behav Brain Res. 2015 Jan 1;276:59-66. doi: 10.1016/j.bbr.2014.04.002. Epub 2014 Apr 18.

25.

The minimum important difference for the Pelvic Organ Prolapse-Urinary Incontinence Sexual Function Questionnaire.

Mamik MM, Rogers RG, Qualls CR, Morrow JD.

Int Urogynecol J. 2014 Oct;25(10):1321-6. doi: 10.1007/s00192-014-2342-9. Epub 2014 Feb 22.

PMID:
24562789
26.

Variation in the form of Pavlovian conditioned approach behavior among outbred male Sprague-Dawley rats from different vendors and colonies: sign-tracking vs. goal-tracking.

Fitzpatrick CJ, Gopalakrishnan S, Cogan ES, Yager LM, Meyer PJ, Lovic V, Saunders BT, Parker CC, Gonzales NM, Aryee E, Flagel SB, Palmer AA, Robinson TE, Morrow JD.

PLoS One. 2013 Oct 1;8(10):e75042. doi: 10.1371/journal.pone.0075042. eCollection 2013.

27.

Increased oxidative stress in patients with depression and its relationship to treatment.

Chung CP, Schmidt D, Stein CM, Morrow JD, Salomon RM.

Psychiatry Res. 2013 Apr 30;206(2-3):213-6. doi: 10.1016/j.psychres.2012.10.018. Epub 2012 Dec 11.

28.

Evolutionary effects of translocations in bacterial genomes.

Morrow JD, Cooper VS.

Genome Biol Evol. 2012;4(12):1256-62. doi: 10.1093/gbe/evs099.

29.

Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.

DuBeau CE, Morrow JD, Kraus SR, Creanga D, Bavendam T.

Neurourol Urodyn. 2012 Nov;31(8):1258-65. doi: 10.1002/nau.22252. Epub 2012 Aug 20.

PMID:
22907761
30.

Quantifying individual variation in the propensity to attribute incentive salience to reward cues.

Meyer PJ, Lovic V, Saunders BT, Yager LM, Flagel SB, Morrow JD, Robinson TE.

PLoS One. 2012;7(6):e38987. doi: 10.1371/journal.pone.0038987. Epub 2012 Jun 22.

31.

The effect of elective sham dose escalation on the placebo response during an antimuscarinic trial for overactive bladder symptoms.

Staskin DR, Michel MC, Sun F, Guan Z, Morrow JD.

J Urol. 2012 May;187(5):1721-6. doi: 10.1016/j.juro.2011.12.052. Epub 2012 Mar 15.

PMID:
22425113
32.

Sex differences in urinary biomarkers of vascular and endothelial function in HIV-infected persons receiving antiretroviral therapy.

Boger MS, Bian A, Shintani A, Milne GL, Morrow JD, Erdem H, Mitchell V, Haas DW, Hulgan T.

Antivir Ther. 2012;17(3):485-93. doi: 10.3851/IMP1990. Epub 2011 Dec 14.

33.

CallSim: Evaluation of Base Calls Using Sequencing Simulation.

Morrow JD, Higgs BW.

ISRN Bioinform. 2012 Dec 12;2012:371718. doi: 10.5402/2012/371718. eCollection 2012.

34.

The fatty acid oxidation product 15-A3t-isoprostane is a potent inhibitor of NFκB transcription and macrophage transformation.

Brooks JD, Musiek ES, Koestner TR, Stankowski JN, Howard JR, Brunoldi EM, Porta A, Zanoni G, Vidari G, Morrow JD, Milne GL, McLaughlin B.

J Neurochem. 2011 Nov;119(3):604-16. doi: 10.1111/j.1471-4159.2011.07422.x. Epub 2011 Sep 23.

35.

PGI synthase overexpression protects against bleomycin-induced mortality and is associated with increased Nqo 1 expression.

Zhou W, Dowell DR, Geraci MW, Blackwell TS, Collins RD, Polosukhin VV, Lawson WE, Wu P, Sussan T, Biswal S, Goleniewska K, O'Neal J, Newcomb DC, Toki S, Morrow JD, Peebles RS Jr.

Am J Physiol Lung Cell Mol Physiol. 2011 Oct;301(4):L615-22. doi: 10.1152/ajplung.00224.2010. Epub 2011 Jul 15.

36.

Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder.

Staskin D, Khullar V, Michel MC, Morrow JD, Sun F, Guan Z, Dmochowski R.

Neurourol Urodyn. 2011 Nov;30(8):1480-5. doi: 10.1002/nau.21099. Epub 2011 May 10.

PMID:
21560158
37.

Use of Gilliam Asperger's disorder scale in differentiating high and low functioning autism and ADHD.

Mayes SD, Calhoun SL, Murray MJ, Morrow JD, Yurich KK, Cothren S, Purichia H, Bouder JN.

Psychol Rep. 2011 Feb;108(1):3-13.

PMID:
21526585
38.

Individual variation in the propensity to attribute incentive salience to an appetitive cue predicts the propensity to attribute motivational salience to an aversive cue.

Morrow JD, Maren S, Robinson TE.

Behav Brain Res. 2011 Jun 20;220(1):238-43. doi: 10.1016/j.bbr.2011.02.013. Epub 2011 Feb 21.

39.

Biomarker responses and disease susceptibility in juvenile rainbow trout Oncorhynchus mykiss fed a high molecular weight PAH mixture.

Bravo CF, Curtis LR, Myers MS, Meador JP, Johnson LL, Buzitis J, Collier TK, Morrow JD, Laetz CA, Loge FJ, Arkoosh MR.

Environ Toxicol Chem. 2011 Mar;30(3):704-14. doi: 10.1002/etc.439. Epub 2011 Jan 13.

PMID:
21298713
40.

Early onset of fesoterodine efficacy in subjects with overactive bladder.

Goldman HB, Morrow JD, Gong J, Tseng LJ, Schneider T.

BJU Int. 2011 Feb;107(4):598-602. doi: 10.1111/j.1464-410X.2010.09586.x. Epub 2010 Sep 24.

41.

Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study.

Wyndaele JJ, Goldfischer ER, Morrow JD, Gong J, Tseng LJ, Choo MS.

BJU Int. 2011 Feb;107(4):603-11. doi: 10.1111/j.1464-410X.2010.09587.x. Epub 2010 Sep 22.

42.

p66(shc)'s role as an essential mitophagic molecule in controlling neuronal redox and energetic tone.

Kleman AM, Brown JE, Zeiger SL, Hettinger JC, Brooks JD, Holt B, Morrow JD, Musiek ES, Milne GL, McLaughlin B.

Autophagy. 2010 Oct;6(7):948-9. doi: 10.1523/j.neurosci.6366-09.2010. Epub 2010 Oct 14.

43.

Essential role of the redox-sensitive kinase p66shc in determining energetic and oxidative status and cell fate in neuronal preconditioning.

Brown JE, Zeiger SL, Hettinger JC, Brooks JD, Holt B, Morrow JD, Musiek ES, Milne G, McLaughlin B.

J Neurosci. 2010 Apr 14;30(15):5242-52. doi: 10.1523/JNEUROSCI.6366-09.2010.

44.

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.

Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J.

BJU Int. 2010 Jan;105(1):58-66. doi: 10.1111/j.1464-410X.2009.09086.x.

45.

Efficacy of fesoterodine over 24 hours in subjects with overactive bladder.

Staskin D, Michel MC, Nitti V, Morrow JD, Wang J, Guan Z.

Curr Med Res Opin. 2010 Apr;26(4):813-8. doi: 10.1185/03007990903585707.

PMID:
20121659
46.

Comparison of three oxidative stress biomarkers in a sample of healthy adults.

Watters JL, Satia JA, da Costa KA, Boysen G, Collins LB, Morrow JD, Milne GL, Swenberg JA.

Biomarkers. 2009 Dec;14(8):587-95. doi: 10.3109/13547500903183954.

47.

Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder.

Dmochowski RR, Peters KM, Morrow JD, Guan Z, Gong J, Sun F, Siami P, Staskin DR.

Urology. 2010 Jan;75(1):62-8. doi: 10.1016/j.urology.2009.09.018. Epub 2009 Nov 22. Erratum in: Urology. 2010 Jun;75(6):1519. Urology. 2011 Jun;77(6):1513.

PMID:
19931895
48.

Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study.

Boger MS, Shintani A, Redhage LA, Mitchell V, Haas DW, Morrow JD, Hulgan T.

J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):480-7.

49.

Dietary fish oil exerts hypolipidemic effects in lean and insulin sensitizing effects in obese LDLR-/- mice.

Saraswathi V, Morrow JD, Hasty AH.

J Nutr. 2009 Dec;139(12):2380-6. doi: 10.3945/jn.109.111567. Epub 2009 Oct 28.

50.

Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients.

Kekatpure VD, Boyle JO, Zhou XK, Duffield-Lillico AJ, Gross ND, Lee NY, Subbaramaiah K, Morrow JD, Milne G, Lippman SM, Dannenberg AJ.

Cancer Prev Res (Phila). 2009 Nov;2(11):957-65. doi: 10.1158/1940-6207.CAPR-09-0093. Epub 2009 Oct 20.

Supplemental Content

Loading ...
Support Center